Diversified Trust Co Buys 1,123 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Diversified Trust Co lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 93.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,330 shares of the biopharmaceutical company’s stock after acquiring an additional 1,123 shares during the period. Diversified Trust Co’s holdings in Regeneron Pharmaceuticals were worth $1,660,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in REGN. International Assets Investment Management LLC raised its stake in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $127,489,000. Icon Wealth Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 18,342.0% during the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after purchasing an additional 75,569 shares during the period. State Street Corp lifted its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in Regeneron Pharmaceuticals by 12.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after purchasing an additional 59,769 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

REGN has been the topic of several research reports. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. Citigroup assumed coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price objective for the company. Piper Sandler cut their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $1,044.48.

Regeneron Pharmaceuticals Price Performance

REGN opened at $733.59 on Thursday. The firm has a 50-day moving average price of $756.46 and a 200-day moving average price of $966.75. Regeneron Pharmaceuticals, Inc. has a twelve month low of $693.00 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $80.61 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 2.19 and a beta of 0.10.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.